Granted Patent
B2
US 12,466,896 · App. 17/930,018 · Granted Nov 11, 2025
Anti-CD3 antibodies and methods of use
Inventors:
Xiaocheng Chen (Foster City, CA); Mark S. Dennis (San Carlos, CA); Allen J. Ebens, Jr. (San Carlos, CA); Robert F. Kelley (Petaluma, CA); Mary A. Mathieu (San Francisco, CA); Liping L. Sun (South San Francisco, CA)
Assignee:
Genentech, Inc.
C07K16/32A61K31/573A61K39/39558A61K45/06A61K47/6881C07K16/2809C07K16/2827C07K16/283C07K16/2863C07K16/2887C07K16/2896C07K16/30A61K2039/505C07K2317/21C07K2317/24C07K2317/31C07K2317/33C07K2317/34C07K2317/522C07K2317/524C07K2317/526C07K2317/54C07K2317/55C07K2317/56C07K2317/622C07K2317/71C07K2317/73C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
Claims (53)
1 . A method of producing a bispecific antibody that binds to CD20 and CD3,
the method comprising culturing host cells expressing one or more isolated nucleic acids, the one or more isolated nucleic acids encoding the bispecific antibody, wherein the bispecific antibody comprises:
(a) an anti-CD20 arm comprising a first binding domain, the first binding domain comprising:
a hypervariable region (HVR)-H1 comprising the amino acid sequence of SEQ ID NO: 157,
an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 158,
an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 159,
an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 160,
an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 161, and
an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 162; and
(b) an anti-CD3 arm comprising a second binding domain, the second binding domain comprising:
an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1,
an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2,
an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3,
an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 4,
an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and
an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
2 . The method of claim 1 , wherein the first binding domain comprises:
(a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 266; (b) a heavy chain light (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 267; or (c) a VH domain as in (a) and a VL domain as in (b),
and the second binding domain comprises:
(a) a VH domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 184; (b) a VL domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 185; or (c) a VH domain as in (a) and a VL domain as in (b).
3 . The method of claim 1 , wherein the second binding domain binds to a human CD3ε polypeptide and/or a cynomolgus monkey (cyno) CD3ε polypeptide.
4 . The method of claim 1 , wherein the bispecific antibody comprises a substitution mutation in the Fc region that reduces effector function.
5 . The method of claim 4 , wherein the substitution mutation is an aglycosylation site mutation.
6 . The method of claim 5 , wherein the aglycosylation site mutation is at amino acid residue N297, L234, L235, and/or D265 (EU numbering).
7 . The method of claim 6 , wherein the aglycosylation site mutation is selected from the group consisting of N297G, N297A, L234A, L235A, and D265A.
8 . The method of claim 1 , wherein the host cells comprise one or more vectors comprising the one or more isolated nucleic acids.
9 . The method of claim 1 , wherein the host cells are mammalian cells.
10 . The method of claim 9 , wherein the mammalian cells are Chinese hamster ovary (CHO), Y0, NS0, or Sp20 cells.
11 . The method of claim 10 , wherein the mammalian cells are CHO cells.
12 . The method of claim 1 , wherein the host cells are prokaryotic cells.
13 . The method of claim 12 , wherein the prokaryotic cells are E. coli cells.
14 . The method of claim 1 , further comprising recovering the bispecific antibody from the host cells or culture medium.
15 . The method of claim 1 , further comprising recovering the anti-CD20 arm and the anti-CD3 arm from the host cells or culture medium.
16 . The method of claim 15 , further comprising contacting the recovered anti-CD20 arm with the recovered anti-CD3 arm.
17 . The method of claim 1 , wherein the bispecific antibody is a monoclonal, humanized, or chimeric antibody.
18 . The method of claim 1 , wherein the bispecific antibody is a full-length antibody.
19 . The method of claim 1 , wherein the bispecific antibody is an antibody fragment that binds CD20 and CD3.
20 . The method of claim 1 , wherein the bispecific antibody is an IgG antibody.
21 . A method of producing a bispecific antibody that binds to CD20 and CD3,
the method comprising culturing host cells expressing one or more isolated nucleic acids, the one or more isolated nucleic acids encoding the bispecific antibody,
wherein the bispecific antibody comprises an anti-CD20 arm comprising a first binding domain comprising (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 266 and (b) a VL domain comprising the amino acid sequence of SEQ ID NO: 267, and an anti-CD3 arm comprising a second binding domain comprising (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 184 and (b) a VL domain comprising the amino acid sequence of SEQ ID NO: 185.
22 . The method of claim 21 , wherein the host cells comprise one or more vectors comprising the one or more isolated nucleic acids.
23 . The method of claim 21 , wherein the host cells are CHO cells.
24 . The method of claim 21 , further comprising recovering the bispecific antibody from the host cells or culture medium.
25 . The method of claim 21 , further comprising recovering the anti-CD20 arm and the anti-CD3 arm from the host cells or culture medium.
26 . The method of claim 25 , further comprising contacting the recovered anti-CD20 arm with the recovered anti-CD3 arm.
27 . A method of producing a bispecific antibody that binds to CD20 and CD3,
the method comprising culturing CHO cells expressing one or more isolated nucleic acids, the one or more isolated nucleic acids encoding the bispecific antibody,
wherein the bispecific antibody comprises an anti-CD20 arm comprising a first binding domain comprising (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 266 and (b) a VL domain comprising the amino acid sequence of SEQ ID NO: 267, and an anti-CD3 arm comprising a second binding domain comprising (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 184 and (b) a VL domain comprising the amino acid sequence of SEQ ID NO: 185, wherein (a) the anti-CD3 arm comprises T366S, L368A, Y407V, and N297G substitution mutations and (b) the anti-CD20 arm comprises T366W and N297G substitution mutations (EU numbering).
28 . The method of claim 27 , wherein the CHO cells comprise one or more vectors comprising the one or more isolated nucleic acids.
29 . The method of claim 27 , further comprising recovering the bispecific antibody from the CHO cells or culture medium.
30 . The method of claim 27 , further comprising recovering the anti-CD20 arm and the anti-CD3 arm from the CHO cells or culture medium.
31 . The method of claim 30 , further comprising contacting the recovered anti-CD20 arm with the recovered anti-CD3 arm.
Continuity (9)
Provisional Application
62091441
· Dec 12, 2014
Provisional Application
62053582
· Sep 22, 2014
Provisional Application
62026594
· Jul 18, 2014
Provisional Application
61949950
· Mar 7, 2014
Provisional Application
61917346
· Dec 17, 2013
References Cited (317)
US 5500362A
· Robinson et al.
· 1996
[cited by applicant]
US 5624821A
· Winter et al.
· 1997
[cited by applicant]
US 5648260A
· Winter et al.
· 1997
[cited by applicant]
US 5677171A
· Hudziak et al.
· 1997
[cited by applicant]
US 5731168A
· Carter et al.
· 1998
[cited by applicant]
US 5821337A
· Carter et al.
· 1998
[cited by applicant]
US 5869046A
· Presta et al.
· 1999
[cited by applicant]
US 6194551B1
· Idusogie et al.
· 2001
[cited by applicant]
US 6248516B1
· Winter et al.
· 2001
[cited by applicant]
US 6455043B1
· Grillo-Lopez
· 2002
[cited by applicant]
US 6602684B1
· Umana et al.
· 2003
[cited by applicant]
US 6737056B1
· Presta
· 2004
[cited by applicant]
US 7332581B2
· Presta
· 2008
[cited by applicant]
US 7371826B2
· Presta
· 2008
[cited by applicant]
US 7435797B2
· Lowman et al.
· 2008
[cited by applicant]
US 7612181B2
· Wu et al.
· 2009
[cited by applicant]
US 7682612B1
· White et al.
· 2010
[cited by applicant]
US 7695936B2
· Carter et al.
· 2010
[cited by applicant]
US 7799900B2
· Adams et al.
· 2010
[cited by applicant]
US 8219149B2
· Lafata et al.
· 2012
[cited by applicant]
US 8258268B2
· Wu et al.
· 2012
[cited by applicant]
US 8562992B2
· Adams et al.
· 2013
[cited by applicant]
US 8709421B2
· Heiss et al.
· 2014
[cited by applicant]
US 8722859B2
· Miller et al.
· 2014
[cited by applicant]
US 8969526B2
· Baehner et al.
· 2015
[cited by applicant]
US 9011864B2
· Schulz et al.
· 2015
[cited by applicant]
US 9017676B2
· Lindhofer
· 2015
[cited by applicant]
US 9308257B2
· Sharma, Sr. et al.
· 2016
[cited by applicant]
US 9315567B2
· Chang et al.
· 2016
[cited by applicant]
US 9493563B2
· Blein et al.
· 2016
[cited by applicant]
US 9587021B2
· Huang et al.
· 2017
[cited by applicant]
US 9657102B2
· Smith et al.
· 2017
[cited by applicant]
US 9714294B2
· De Goeij et al.
· 2017
[cited by applicant]
US 20030157108A1
· Presta
· 2003
[cited by applicant]
US 20040093621A1
· Shitara et al.
· 2004
[cited by applicant]
US 20040110704A1
· Yamane et al.
· 2004
[cited by applicant]
US 20040132140A1
· Satoh et al.
· 2004
[cited by applicant]
US 20050095243A1
· Chan et al.
· 2005
[cited by applicant]
US 20100150918A1
· Kufer et al.
· 2010
[cited by applicant]
US 20130129723A1
· Blankenship et al.
· 2013
[cited by applicant]
US 20130165638A1
· Hsu et al.
· 2013
[cited by applicant]
US 20140170148A1
· De Goeij et al.
· 2014
[cited by applicant]
US 20140170149A1
· Neijssen et al.
· 2014
[cited by applicant]
US 20160017058A1
· Kim et al.
· 2016
[cited by applicant]
US 20160090416A1
· Gunde et al.
· 2016
[cited by applicant]
US 20170008971A1
· Dennis et al.
· 2017
[cited by applicant]
US 20170158773A1
· Adams et al.
· 2017
[cited by applicant]
US 20170224818A1
· Lindhofer et al.
· 2017
[cited by applicant]
US 20180057593A1
· Dennis
· 2018
[cited by applicant]
US 20200339686A1
· Sato et al.
· 2020
[cited by applicant]
CN 101675077B
· 2013
[cited by applicant]
EP 1870459A1
· 2007
[cited by applicant]
EP 1870459A4
· 2010
[cited by applicant]
EP 2482212A1
· 2012
[cited by applicant]
EP 2578230A1
· 2013
[cited by applicant]
EP 2647707A1
· 2013
[cited by applicant]
EP 2647707A4
· 2014
[cited by applicant]
EP 1870459B1
· 2016
[cited by applicant]
JP 2008291036A
· 2008
[cited by applicant]
JP 2009539413A
· 2009
[cited by applicant]
JP 2010524435A
· 2010
[cited by applicant]
JP 2013515509A
· 2013
[cited by applicant]
JP 2013528569A
· 2013
[cited by applicant]
JP 2013529084A
· 2013
[cited by applicant]
JP 2015509952A
· 2015
[cited by applicant]
WO WO9103493A1
· 1991
[cited by applicant]
WO WO9404679A1
· 1994
[cited by applicant]
WO WO9429351A2
· 1994
[cited by applicant]
WO WO9601126A1
· 1996
[cited by applicant]
WO WO9627011A1
· 1996
[cited by applicant]
WO WO9730087A1
· 1997
[cited by applicant]
WO WO9850431A2
· 1998
[cited by applicant]
WO WO9858964A1
· 1998
[cited by applicant]
WO WO9850431A3
· 1999
[cited by applicant]
WO WO9922764A1
· 1999
[cited by applicant]
WO WO9951642A1
· 1999
[cited by applicant]
WO WO0061739A1
· 2000
[cited by applicant]
WO WO0129246A1
· 2001
[cited by applicant]
WO WO0231140A1
· 2002
[cited by applicant]
WO WO03011878A2
· 2003
[cited by applicant]
WO WO03084570A1
· 2003
[cited by applicant]
WO WO03085107A1
· 2003
[cited by applicant]
WO WO03085119A1
· 2003
[cited by applicant]
WO WO03087131A2
· 2003
[cited by applicant]
WO WO2004056312A2
· 2004
[cited by applicant]
WO WO2005035586A1
· 2005
[cited by applicant]
WO WO2005035778A1
· 2005
[cited by applicant]
WO WO2005053742A1
· 2005
[cited by applicant]
WO WO2005100402A1
· 2005
[cited by applicant]
WO WO2006029879A2
· 2006
[cited by applicant]
WO WO2007042261A2
· 2007
[cited by applicant]
WO WO2007110205A2
· 2007
[cited by applicant]
WO WO2007146968A2
· 2007
[cited by applicant]
WO WO2008077546A1
· 2008
[cited by applicant]
WO WO2008119566A2
· 2008
[cited by applicant]
WO WO2008119567A2
· 2008
[cited by applicant]
WO WO2009070642A1
· 2009
[cited by applicant]
WO WO2009106321A1
· 2009
[cited by applicant]
WO WO2010077643A1
· 2010
[cited by applicant]
WO WO2010114940A1
· 2010
[cited by applicant]
WO WO2011028952A1
· 2011
[cited by applicant]
WO WO2011090754A1
· 2011
[cited by applicant]
WO WO2011090762A1
· 2011
[cited by applicant]
WO WO2011121110A1
· 2011
[cited by applicant]
WO WO2011131746A2
· 2011
[cited by applicant]
WO WO2011143545A1
· 2011
[cited by applicant]
WO WO2012058768A1
· 2012
[cited by applicant]
WO WO2012058768A8
· 2012
[cited by applicant]
WO WO2012073985A1
· 2012
[cited by applicant]
WO WO2012075581A1
· 2012
[cited by applicant]
WO WO2012123949A1
· 2012
[cited by applicant]
WO WO2012143524A2
· 2012
[cited by applicant]
WO WO2012158818A2
· 2012
[cited by applicant]
WO WO2012162067A2
· 2012
[cited by applicant]
WO WO2013128194A1
· 2013
[cited by applicant]
WO WO2014022540A1
· 2014
[cited by applicant]
WO WO2014028560A2
· 2014
[cited by applicant]
WO WO2014047231A1
· 2014
[cited by applicant]
WO WO2014028560A3
· 2014
[cited by applicant]
WO WO2014083178A1
· 2014
[cited by applicant]
WO WO2014108483A1
· 2014
[cited by applicant]
WO WO2014122251A2
· 2014
[cited by applicant]
WO WO2014141152A2
· 2014
[cited by applicant]
WO WO2014144722A2
· 2014
[cited by applicant]
WO WO2014153002A1
· 2014
[cited by applicant]
WO WO2014122251A3
· 2014
[cited by applicant]
WO WO2014170063A1
· 2014
[cited by applicant]
WO WO2014141152A3
· 2014
[cited by applicant]
WO WO2014191113A1
· 2014
[cited by applicant]
WO WO2014193973A2
· 2014
[cited by applicant]
WO WO2015006749A2
· 2015
[cited by applicant]
WO WO2015013671A1
· 2015
[cited by applicant]
WO WO2014191113A8
· 2015
[cited by applicant]
WO WO2015095392A1
· 2015
[cited by applicant]
WO WO2015143079A1
· 2015
[cited by applicant]
WO WO2015184203A1
· 2015
[cited by applicant]
WO WO2015184207A1
· 2015
[cited by applicant]
WO WO2016014942A1
· 2016
[cited by applicant]
WO WO2016019969A1
· 2016
[cited by applicant]
WO WO2016020065A1
· 2016
[cited by applicant]
WO WO2016036678A1
· 2016
[cited by applicant]
WO WO2016135239A1
· 2016
[cited by applicant]
WO WO2016179003A1
· 2016
[cited by applicant]
WO WO2016191750A1
· 2016
[cited by applicant]
WO WO2016201300A1
· 2016
[cited by applicant]
WO WO2016204966A1
· 2016
[cited by applicant]
WO WO2016205520A1
· 2016
[cited by applicant]
WO WO2016205531A2
· 2016
[cited by applicant]
WO WO2017132279A1
· 2017
[cited by applicant]
WO WO2018093821A1
· 2018
[cited by applicant]
Anderson et al., “G19.4(alpha CD3) x B43(alpha CD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T c…
[cited by applicant]
Atwell et al., “Stable Heterodimers from Remodeling the Domain Interface of a Homodimer using a Phage Display Library,” J Mol Biol. 270(1):26-35 (1997).
[cited by applicant]
Baeuerle et al., “Bispecific T-cell engaging antibodies for cancer therapy,” Cancer Res. 69(12):4941-4 (2009).
[cited by applicant]
Bortoletto et al., “Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells,” Eur J Immunol. 32(11):3102-7 (2002).
[cited by applicant]
Brack et al., “A Bispecific HER2-Targeting FynomAb with Superior Antitumor Activity and Novel Mode of Action,” Mol Cancer Ther. 13(8):2030-39 (2014) (11 pages).
[cited by applicant]
Brekke et al., “Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytosis,” Eur J Immunol. 24(10):2542-7 (1994).
[cited by applicant]
Brinkmann et al., “The making of bispecific antibodies,” mAbs. 9(2):182-212 (2017).
[cited by applicant]
Brown et al., “Tolerance of single, but not multiple, amino acid replacements in antibody VH CDR2: a means of minimizing B cell wastage from somatic hypermutation?” J Immunol. 156(9):3285-91 (1996).
[cited by applicant]
Brüggemann et al., “Comparison of the Effector Functions of Human Immunoglobulins Using a Matched set of Chimeric Antibodies,” J Exp Med. 166(5):1351-61 (1987).
[cited by applicant]
Budde et al., “Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study,” B…
[cited by applicant]
Carter, “Bispecific human lgG by design,” J Immunol Methods. 248(1-2):7-15 (2001).
[cited by applicant]
Choi et al., “Bispecific antibodies engage T cells for antitumor immunotherapy,” Expert Opin Biol Ther. 11(7):843-53 (2011).
[cited by applicant]
Clark et al., “Affinity enhancement of an in vivo matured therapeutic antibody using structure-based computational design,” Protein Sci. 15(5):949-60 (2006).
[cited by applicant]
Clynes et al., “Fc receptors are required in passive and active immunity to melanoma,” Proc Natl Acad Sci U S A. 95(2):652-6 (1998).
[cited by applicant]
Cragg et al., “Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents,” Blood. 103(7):2738-43 (2004).
[cited by applicant]
Cragg et al., “Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts,” Blood. 101(3):1045-52 (2003).
[cited by applicant]
Desnoyers et al., “Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index,” Sci Transl Med. 5(207):207ra144 (2013) (10 pages).
[cited by applicant]
Donaldson et al., “Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies,” Cancer Biol Ther. 8(22): 2145-50 (2009) (6 pages).
[cited by applicant]
Drent et al., “A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization,” Mol Ther. 25(8):1946-58 (2017).
[cited by applicant]
Duncan et al., “The binding site for C1q on lgG,” Nature. 332(6166):738-40 (1988).
[cited by applicant]
Edelman et al., “The covalent structure of an entire gammaG immunoglobulin molecule,” Proc Natl Acad Sci U S A. 63(1):78-85 (1969).
[cited by applicant]
Gazzano-Santoro et al., “A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody,” J Immunol Methods. 202(2):163-71 (1997).
[cited by applicant]
Genentech, “A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers,” ClinicalTrials.gov, <https://clinicaltrials.gov/ct2/show/NCT03448042?term=BTRC4017 A&draw=2&rank=1>,…
[cited by applicant]
Guyer et al., “Immunoglobulin binding by mouse intestinal epithelial cell receptors,” J Immunol. 117(2):587-93 (1976).
[cited by applicant]
Hellström et al., “Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas,” Proc Natl Acad Sci U S A. 83(18):7059-63 (1986).
[cited by applicant]
Hellström et al., “Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside,” Proc Natl Acad Sci U S A. 82(5):1499-502 (1985).
[cited by applicant]
Hernandez et al., “Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma,” Blood. 134(Supplement 1):1585 (2019) (4 pag…
[cited by applicant]
Holliger et al., “Diabodies': small bivalent and bispecific antibody fragments,” Proc Natl Acad Sci USA. 90(14):6444-8 (1993).
[cited by applicant]
Holliger et al., “Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody,” Protein Eng. 9(3):299-305 (1996).
[cited by applicant]
Honeychurch et al., “Bispecific Ab therapy of B-cell lymphoma: target cell specificity of antibody derivatives appears critical in determining therapeutic outcome,” Cancer Immunol Immunother. 45(3-4):171-3 (1997).
[cited by applicant]
Hosseini et al., “Systems pharmacology modeling of anti-CD20/CD3 T-cell dependent bispecific antibody and its application to clinical trial design,” American Conference on Pharmacometrics 7; Oct. 25; Bellevue, WA. (2016…
[cited by applicant]
Huang et al., “In Vivo Deamidation Characterization of Monoclonal Antibody by LC/MS/MS,” Anal Chem. 77(5):1432-9 (2005).
[cited by applicant]
Hudson et al., “Engineered antibodies,” Nat Med. 9(1):129-34 (2003).
[cited by applicant]
Idusogie et al., “Mapping of the C1q Binding Site on Rituxan, A Chimeric Antibody with a Human IgG1 Fc,” J Immunol. 164(8):4178-84 (2000).
[cited by applicant]
Igawa et al., “VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist single-chain diabody,” Protein Eng Des Sel. 23(8):667-77 (2010) (11 …
[cited by applicant]
Jager et al., “The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2,” Cancer Res. 69(10):4270-6 (2009).
[cited by applicant]
Junttila et al., “Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells,” Cancer Res. 74(19):5561-71 (2014).
[cited by applicant]
Kanda et al., “Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC,” Biotechnol Bioeng. 94(4):680-8 (2006).
[cited by applicant]
Kegg Drug Database Accession No. D03257, “Drug: Trastuzumab,” <https://www.genome.jp/dbget-bin/www_bget?dr:D03257>, retrieved on Jan. 8, 2019 (2 pages).
[cited by applicant]
Kelley et al., “ Thermodynamic Analysis of an Antibody Functional Epitope,” Biochemistry. 32(27):6828-35 (1993).
[cited by applicant]
Kiewe et al., “Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer,” 2005 ASCO Annual Meeting Proceedings. J Clin Oncol. 23(16S):Abstract 2530 (2005) (1 page).
[cited by applicant]
Kiewe et al., “Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer,” Clin Cancer Res. 12(10):3085-91 (2006).
[cited by applicant]
Kim et al., “Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor,” Eur J Immunol. 24(10):2429-34 (1994).
[cited by applicant]
Kipriyanov et al., “Bispecific Tandem Diabody for Tumor Therapy with Improved Antigen Binding and Pharmacokinetics,” J Mol Biol. 293(1):41-56 (1999).
[cited by applicant]
Klein et al., “Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies,” MAbs. 4(6):653-63 (2012).
[cited by applicant]
Kontermann, “Dual targeting strategies with bispecific antibodies,” MAbs. 4(2):182-97 (2012).
[cited by applicant]
Law et al., “Expression and characterization of recombinant soluble human CD3 molecules: presentation of antigenic epitopes defined on the native TCR-CD3 complex” Int Immunol 14(4):389-400 (2002).
[cited by applicant]
Leabman et al., “Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys,” mAbs. 5(6):896-903 (2013).
[cited by applicant]
Lee et al., “Current concepts in the diagnosis and management of cytokine release syndrome,” Blood. 124(2):188-95 (2014) (18 pages).
[cited by applicant]
Li, “Successful QSP modeling in drug development starts with the right questions,” American Conference on Pharmacometrics 8, Oct. 16, Fort Lauderdale, FL. (2017) (20 pages).
[cited by applicant]
Lippow et al., “Computational design of antibody affinity improvement beyond in vivo maturation,” available in PMC Jan. 7, 2010, published in final edited form as: Nat Biotechnol. 25(10):1171-6 (2007) (14 pages).
[cited by applicant]
Liu et al., “Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice,” Cancer Res. 75(17):3596-607 (2015) (13 pages).
[cited by applicant]
Liu et al., “Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes,” Proc Natl Acad Sci U S A. 82(24):8648-52 (1985).
[cited by applicant]
Liu et al., “Improvement in soluble expression levels of a diabody by exchanging expression vectors,” Protein Expr Purif. 62(1): 15-20 (2008) (6 pages).
[cited by applicant]
Lum et al., “Targeting T cells with bispecific antibodies for cancer therapy,” available in PMC Oct. 8, 2013, published in final edited form as: BioDrugs. 25(6):365-79 (2011) (24 pages).
[cited by applicant]
Merchant et al., “An efficient route to human bispecific IgG,” Nat Biotechnol. 16(7):677-81 (1998).
[cited by applicant]
Metz et al., “Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing,” Protein Eng Des Sel. 25(10):571-80 (2012).
[cited by applicant]
Moore et al., “Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma,” Blood. 117(17):4542-51 (2011) (11 pages).
[cited by applicant]
Nagorsen et al., “Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab,” Exp Cell Res. 317(9):1255-60 (2011).
[cited by applicant]
Nishimoto et al., “Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study,” J Rheumatol.…
[cited by applicant]
Okazaki et al., “Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa,” J Mol Biol. 336(5):1239-49 (2004).
[cited by applicant]
Pessano et al., “The T3/T cell receptor complex: antigenic distinction between the two 20-kd T3 (T3-delta and T3-epsilon) subunits,” EMBO J. 4(2):337-44 (1985).
[cited by applicant]
Petkova et al., “Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease,” Int Immunol. 18(12):1759-69 (2006).
[cited by applicant]
Ravetch et al., “Fc receptors,” Annu Rev Immunol. 9:457-92 (1991).
[cited by applicant]
Reusch et al., “Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model,” Clin Cancer Res. 12(1):183-90 (2…
[cited by applicant]
Ridgway et al., “'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization,” Protein Eng. 9(7):617-21 (1996).
[cited by applicant]
Riedle et al., “In vivo activation and expansion of T cells by a bi-specific antibody abolishes metastasis formation of human melanoma cells in SCID mice,” Int J Cancer. 75(6):908-18 (1998).
[cited by applicant]
Ripka et al., “Two Chinese hamster ovary glycosylation mutants affected in the conversion of GDP-mannose to GDP-fucose,” Arch Biochem Biophys. 249(2):533-45 (1986).
[cited by applicant]
Roosnek et al., “Triggering T Cells by Otherwise Inert Hybrid Anti-CD3/Antitumor Antibodies Requires Encounter with the Specific Target Cell,” J Exp Med. 170(1):297-302 (1989) (6 pages).
[cited by applicant]
Saphire et al., “Crystal structure of a neutralizing human IgG against HIV-1: a template for vaccine design,” Science. 293(5532):1155-9 (2001).
[cited by applicant]
Seimetz et al., “Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy,” Cancer Treat Rev. 36(6):458-67 (2010).
[cited by applicant]
Sen et al., “Use of Anti-CD3 x Anti-HER2/neu Bispecific Antibody for Redirecting Cytotoxicity of Activated T Cells Toward HER2/neu+ Tumors,” J Hematother Stem Cell Res. 10(2):247-60 (2001).
[cited by applicant]
Shalaby et al., “Bispecific HER2 x CD3 antibodies enhance T-cell cytotoxicity in vitro and localize to HER2-overexpressing xenografts in nude mice,” Clin Immunol Immunopathol. 74(2):185-92 (1995).
[cited by applicant]
Shen et al., “Preparation and characterization for bispecific antibodies of anti-CD3 x anti-idiotype to B cell lymphocytic leukemia,” J Tongji Med Univ. 19(3):166-9 (1999) (4 pages).
[cited by applicant]
Shields et al., “High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR,” J Biol Chem. 276(9):6591-604 (2001).
[cited by applicant]
Sondermann et al., “The 3.2-A crystal structure of the human IgG1 Fc fragment-FcγRIII complex,” Nature. 406(6793):267-73 (2000).
[cited by applicant]
Spiess et al., “Alternative molecular formats and therapeutic applications for bispecific antibodies,” Mol Immunol. 67(2):95-106, retrieved from <https://www.sciencedirect.com/science/article/pii/S016158901500005X?via%3…
[cited by applicant]
Spiess et al., “Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies,” Nat Biotechnol. 31(8):753-8 (2013) (7 pages).
[cited by applicant]
Stanglmaier et al., “Bi20 (FBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels,” Int J Cancer. 123(5):…
[cited by applicant]
Stubenrauch et al., “Impact of molecular processing in the hinge region of therapeutic IgG4 antibodies on disposition profiles in cynomolgus monkeys,” Drug Metab Dispos. 38(1):84-91 (2010).
[cited by applicant]
Sun et al., “Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies,” Sci Transl Med. 7(287):287ra70 (2015) (11 pages).
[cited by applicant]
Weidle et al., “The Intriguing Options of Multispecific Antibody Formats for Treatment of Cancer,” Cancer Genomics Proteomics. 10(1):1-18 (2013) (18 pages).
[cited by applicant]
Westin et al., “Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial,” Lancet Oncol. 15(1):69-77 (2014…
[cited by applicant]
Wright et al., “Effect of glycosylation on antibody function: implications for genetic engineering,” Trends Biotechnol. 15(1):26-32 (1997).
[cited by applicant]
Wuellner et al., “Bispecific CD3/HER2 Targeting FynomAb Induces Redirected T Cell-Mediated Cytolysis with High Potency and Enhanced Tumor Selectivity,” Antibodies. 4(4):426-440 (2015) (15 pages).
[cited by applicant]
Yamane-Ohnuki et al., “Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity,” Biote…
[cited by applicant]
Yan et al., “Succinimide Formation at Asn 55 in the Complementarity Determining Region of a Recombinant Monoclonal Antibody IgG1 Heavy Chain,” J Pharm Sci. 98(10):3509-21 (2009).
[cited by applicant]
Yang et al., “Improving Trastuzumab's Stability Profile by Removing the Two Degradation Hotspots,” J Pharm Sci. 104(6):1960-70 (2015).
[cited by applicant]
Zhu et al., “Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F(ab')2 for efficient lysis of p185HER2 overexpressing tumor cells,” Int J Cancer. 62(3):319-24 (1995).
[cited by applicant]
Zhu et al., “Identification of heavy chain residues in a humanized anti-CD3 antibody important for efficient antigen binding and T cell activation,” J Immunol. 155(4):1903-10 (1995).
[cited by applicant]
Communication pursuant to Article 94(3) dated Apr. 10, 2017, for Chen et al., “ANTI-CD3 Antibodies and Methods of Use,” European Patent Application No. 14828608.1, filed Dec. 17, 2014 (7 pages).
[cited by applicant]
Communication pursuant to Article 94(3) dated Aug. 2, 2018, for Chen et al., “ANTI-CD3 Antibodies and Methods of Use,” European Patent Application No. 14828608.1, filed Dec. 17, 2014 (10 pages).
[cited by applicant]
Communication pursuant to Article 94(3) dated Nov. 8, 2017, for Chen et al., “ANTI-CD3 Antibodies and Methods of Use,” European Patent Application No. 14828608.1, filed Dec. 17, 2014 (11 pages).
[cited by applicant]
Communication pursuant to Article 94(3) EPC for European Patent Application No. 14828608.1, dated Jul. 31, 2019 (4 pages).
[cited by applicant]
Communication pursuant to Article 94(3) EPC for European Patent Application No. 17156352.1, dated Jul. 31, 2019 (4 pages).
[cited by applicant]
Decision Concerning a Rejection of an Invention for Moroccan Patent Application No. 39078, issued Feb. 21, 2019 (9 pages).
[cited by applicant]
Decision to Grant Patent for Japanese Patent Application No. 2017-221759, issued Apr. 9, 2019 (6 pages).
[cited by applicant]
Examination Report dated Aug. 24, 2018, for Chen et al., “ANTI-CD3 Antibodies and Methods of Use,” Singaporean Patent Application No. 10201800250X, filed Dec. 17, 2014 (4 pages).
[cited by applicant]
Examination Report for Australian Patent Application No. 2014364805, dated Feb. 11, 2019 (3 pages).
[cited by applicant]
Examination Report for Gulf Cooperation Council Patent Application No. 2014-34716, dated Mar. 19, 2019 (5 pages).
[cited by applicant]
Examination Report for Malaysian Patent Application No. PI 2016001124, mailed Sep. 20, 2019 (2 pages).
[cited by applicant]
Extended European Search Report dated May 29, 2017, for Chen et al., “ANTI-CD3 Antibodies and Methods of Use,” European Patent Application No. 17156352.1, filed Dec. 17, 2014 (10 pages).
[cited by applicant]
First Examination Report for New Zealand Patent Application No. 721309, dated Nov. 12, 2018 (5 pages).
[cited by applicant]
International Preliminary Report on Patentability issued Dec. 19, 2017, for Hotzel et al., “Humanized and Affinity Matured Antibodies To FCRH5 and Methods of Use,” International Patent Application No. PCT/US2016/037879,…
[cited by applicant]
International Preliminary Report on Patentability issued Jun. 21, 2016, for Chen et al., “ANTI-CD3 Antibodies and Methods of Use,” International Patent Application No. PCT/US2014/070951, filed Dec. 17, 2014 (19 pages).
[cited by applicant]
International Preliminary Report on Patentability issued Nov. 7, 2017, for Dennis, “Masked ANTI-CD3 Antibodies and Methods of Use,” International Patent Application No. PCT/US2016/030127, filed Apr. 29, 2016 (9 pages).
[cited by applicant]
International Search Report and Written Opinion mailed Aug. 3, 2016 for Dennis, “Masked ANTI-CD3 Antibodies and Methods of Use,” International Patent Application No. PCT/US2016/030127, filed Apr. 29, 2016 (15 pages).
[cited by applicant]
International Search Report and Written Opinion mailed May 28, 2015, for Chen et al., “ANTI-CD3 Antibodies and Methods of Use,” International Patent Application No. PCT/US2014/070951, filed Dec. 17, 2014 (33 pages).
[cited by applicant]
International Search Report and Written Opinion mailed Nov. 4, 2016, for Hotzel et al., “Humanized and Affinity Matured Antibodies To FCRH5 and Methods of Use,” International Patent Application No. PCT/US2016/037879, fi…
[cited by applicant]
Invitation to Pay Additional Fees mailed Apr. 9, 2015, for Chen et al., “ANTI-CD3 Antibodies and Methods of Use,” International Patent Application No. PCT/US2014/070951, filed Dec. 17, 2014 (12 pages).
[cited by applicant]
Invitation to Pay Additional Fees mailed Sep. 12, 2016, for Hotzel et al., “Humanized and Affinity Matured Antibodies To FCRH5 and Methods of Use,” International Patent Application No. PCT/US2016/037879, filed Jun. 16, …
[cited by applicant]
Notice of Reasons for Rejection dated Dec. 19, 2017, for Chen et al., “ANTI-CD3 Antibodies and Methods of Use,” Japanese Patent Application No. 2016-539276, filed Dec. 17, 2014 (6 pages).
[cited by applicant]
Notice of Reasons for Rejection dated Jul. 31, 2018, for Chen et al., “ANTI-CD3 Antibodies and Methods of Use,” Japanese Patent Application No. 2016-539276, filed Dec. 17, 2014 (6 pages).
[cited by applicant]
Notice of Reasons for Rejection for Japanese Patent Application No. 2019-044073, issued Jan. 21, 2020 (4 pages).
[cited by applicant]
Notice of Reasons for Rejection of Japanese Patent Application No. 2017-221759, dated Dec. 11, 2018 (6 pages).
[cited by applicant]
Notification of Defects in Israeli Patent Application No. 245945, dated Mar. 14, 2019 (6 pages).
[cited by applicant]
Office Action for Chinese Patent Application No. 201480075726.X, dated Dec. 29, 2018 (11 pages).
[cited by applicant]
Office Action for Colombian Patent Application No. NC2019/0009685, dated Sep. 13, 2019 (15 pages).
[cited by applicant]
Office Action for Eurasian Patent Application No. 201691266, dated Dec. 5, 2018 (5 pages).
[cited by applicant]
Office Action for Eurasian Patent Application No. 201691266, dated Oct. 31, 2019 (5 pages).
[cited by applicant]
Office Action for Israeli Patent Application No. 263466, dated Nov. 23, 2020 (8 pages).
[cited by applicant]
Office Action for U.S. Appl. No. 15/473,242, dated Jul. 25, 2019 (9 pages).
[cited by applicant]
Search Report and Office Action for Taiwanese Patent Application No. 107134362, dated Oct. 17, 2019 (7 pages).
[cited by applicant]
Search Report dated Aug. 24, 2018, for Chen et al., “ANTI-CD3 Antibodies and Methods of Use,” Singaporean Patent Application No. 10201800250X, filed Dec. 17, 2014 (3 pages).
[cited by applicant]
Search Report dated Aug. 29, 2018, for Chen et al., “ANTI-CD3 Antibodies and Methods of Use,” Taiwanese Patent Application No. 103144203, filed Dec. 17, 2014 (2 pages).
[cited by applicant]
Search Report dated Aug. 8, 2017, for Chen et al., “ANTI-CD3 Antibodies and Methods of Use,” Singaporean Patent Application No. 11201604990P, filed Dec. 17, 2014 (6 pages).
[cited by applicant]
Second Office Action for Chinese Patent Application No. 201480075726.X, issued Oct. 21, 2019 (9 pages).
[cited by applicant]
Technical Report Notification for Costa Rican Patent Application No. 2016-0000314, dated Feb. 12, 2020 (10 pages).
[cited by applicant]
Written Opinion for Singaporean Patent Application No. 11201604990P, dated Aug. 8, 2017 (7 pages).
[cited by applicant]
Kortt et al., “Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting,” Biomol Eng. 18:95-108 (2001) (15 pages).
[cited by applicant]